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Topical apraclonidine is readily available and has been used in the past to treat glaucoma with minimal adverse effects. To our knowledge, we report the first use of this agent in the pharmacologic diagnosis of pediatric Horner syndrome. We discussed 4 patients (cases [1] [2] [3] [4] with Horner syndrome, all of whom experienced a reversal of anisocoria after receiving 1% apraclonidine. To contrast this, we discussed an additional 2 patients with anisocoria not related to Horner syndrome (cases 5 and 6), who experienced no change in pupil size. This reversal of anisocoria is easier to observe clinically than the asymmetric mydriasis cocaine produces.
Based on the findings in our cases and the prior article with 6 adult patients with Horner syndrome, apraclonidine may play a role in the diagnosis of Horner syndrome. In fact, the diagnosis of neuroblastoma in case 4 may have been delayed if we had not tested the patient with 1% apraclonidine.
If it could be shown that 0.5% apraclonidine is as effective in causing a reversal of anisocoria in Horner syndrome as 1% apraclonidine, it would be an even more attractive agent to use for this purpose. Adverse effects would be minimized, and 0.5% apraclonidine is more readily available. Although the previously published article using apraclonidine to diagnose adults with Horner syndrome had cases of preganglionic and postganglionic lesions, the number of patients was small. Sensitivity and specificity of this diagnostic test need to be investigated. Also, with all pharmacologic tests based on denervation hypersensitivity, a false-negative result may occur in the acute setting (where denervation hypersensitivity has not yet developed).
Further studies are also necessary to evaluate the safety profile of the instillation of this agent in infants. Another ␣-adrenergic receptor agonist used to lower intraocular pressure, 0.2% brimonidine tartrate, has caused apnea, bradycardia, hypotension, somnolence, and lethargy in children. 6 One of the infants in our study who received 1 drop of 1% apraclonidine in both eyes was somewhat sleepier than usual that afternoon, but this resolved without adverse sequelae. The other patients did not experience any adverse effects. Exposure keratitis occurs in facial nerve palsy and may lead to visual loss resulting from corneal damage unless it is treated appropriately. Tarsorrhaphy may be required in more severe cases. This report describes a simple way of performing temporary tarsorrhaphy in the outpatient setting.
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Report of Cases.
Three consecutive patients with exposure keratopathy were treated with N-butyl-2-cyanoacrylate (Indermil; Henkel Loctite Corporation, Dublin, Ireland) tarsorrhaphy. Indermilassisted tarsorrhaphy is simple and is easily performed in the outpatient setting. The eyelid is cleaned with isotonic sodium chloride solution and thoroughly dried with a cotton bud. The patient is instructed to close his or her eyes, and Indermil is applied directly to the eyelid margin (Figure 1) . The glue should be applied as a thin film by mounting a Southampton (Figure 2) or lacrimal cannula at the end of the tube. Light pressure is then applied to the eyelid margins with cotton buds for 30 seconds to enhance adhesion. The patient is advised to avoid wetting the eyelids for the next few hours. Case 1. A 45-year-old man was seen in the eye casualty service, complaining of decreased vision in the right eye. Four weeks previously, he had undergone surgery to remove an acoustic neuroma. An examination revealed a large central corneal abrasion in the right eye, with absent corneal sensation and lower motor neuron facial nerve palsy (Figure 3) .
Conservative treatment with topical lubricants and antibiotics failed. The patient was offered surgical tarsorrhaphy, but the offer was declined. Instead, Indermil was used to close the lateral eyelids (Figure 4) . The tarsorrhaphy was satisfactory and lasted 4 days, during which the epithelial defect decreased in size. Thereafter, tarsorrhaphy was repeated twice without complications. The second application lasted 7 days, and the corneal abrasion. Chloramphenicol ointment was prescribed, and the patient was advised to tape her left eyelid shut at night. Four days later, corneal exposure with a persistent corneal abrasion was still evident. Surgical tarsorrhaphy was refused; however, the patient consented to tarsorrhaphy with Indermil. The tarsorrhaphy lasted 7 days, during which the corneal abrasion healed. Function of the left facial muscles was restored during this period, and the exposure keratopathy resolved.
Case 3. A 40-year-old man was seen in the eye casualty with a 4-day history of facial nerve palsy secondary to herpes zoster infection. Corneal exposure with a central abrasion was evident. There was 5 mm of lagophthalmos. He was prescribed chloramphenicol ointment and advised to tape his eyelids shut at night. He subsequently developed a skin allergy to the tape and discontinued its use. A subsequent examination found a persistent central corneal abrasion. The patient refused surgical tarsorrhaphy but was agreeable to lateral tarsorrhaphy with Indermil. The first tarsorrhaphy lasted 6 days but his lower eyelid function remained poor, and worsening of the exposure keratitis occurred over the next 5 days. Glue tarsorrhaphy with Indermil was performed on 2 other occasions, each lasting 7 days. At the end of the third application, the corneal defect had healed and eyelid function recovered satisfactorily.
Comment. Exposure keratitis is a complication of facial nerve palsy. Without treatment, this may lead to corneal ulceration with severe visual loss from scarring and infection. In mild cases, exposure keratopathy can be managed conservatively with copious lubricants and eyelid taping, but in severely affected corneas, eyelid closure may be required to maintain corneal integrity. Surgical tarsorrhaphy and botulinum toxin-induced ptosis are 2 well-recognized methods of providing corneal protection. Both are effective but have their disadvantages.
Surgical tarsorraphy may be divided into suture tarsorrhaphy over bolsters (for short-term use) and reversible permanent eyelid adhesion tarsorrhaphy (for longer-term use). The former is commonly accepted as the gold standard for temporary eyelid closure. However, both forms of surgical tarsorrhaphy are time consuming, and there may be a risk of permanent scarring to the eyelids from surgery. In addition, patients often refuse surgical tarsorrhaphy for cosmetic reasons. On the other hand, botulinum toxin may not be available universally because of constraints of cost and expertise. Moreover, the induced ptosis is variable in its onset and duration, and there are risks associated with the injection.
An alternative approach is to perform glue-assisted tarsorrhaphy. Indermil is a tissue adhesive (N-butyl-2-cyanoacrylate monomer) that is widely used in surgery for the closure of skin wounds and internal wounds without the need for suturing. 1 The use of Indermil has also been described in obstetric and gynecologic procedures, otolaryngologic procedures, hand surgery, and plastic and reconstructive surgery. The use of cyanoacrylate glue has been described previously in the management of corneal epithelial defects 2 and other ocular problems. 3 However, there has been little documentation to date on the successful use of licensed medical preparations of tissue glue for tarsorrhaphy.
Indermil-assisted tarsorrhaphy lasts for about a week and can easily be repeated when necessary. With regard to safety, a previous case series has suggested that there is no longterm morbidity from superglue contact with the eye. 4 The technique is not a replacement for surgical tarsorrhaphy; however, it may be considered as an alternative in certain situations. First, the technique can be used to provide short-term corneal protection prior to recovery of facial nerve palsy. Second, it may serve as a temporary measure for exposure keratopathy while awaiting more definitive treatment. Third, it is of value in patients who refuse surgical intervention. 
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